- Sarepta and FDA will continue dialogue on next steps in the safety labeling process and risk-mitigation approach for non-ambulatory patients Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback